Anaplastic Thyroid Cancer (ATC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Anaplastic thyroid carcinoma (ATC), also referred to as undifferentiated carcinoma, is a rare and highly aggressive malignant tumor, constituting approximately 2% to 3% of all thyroid gland neoplasms. ATC is one of the most lethal diseases globally and is associated with a very poor prognosis. It is characterized by significant local invasion and frequently presents with metastatic spread to regional lymph nodes and distant sites. ATC risk factors include low educational level, type B blood group and goiter. Patients with poorly differentiated thyroid cancer exhibiting specific characteristics tend to present with more complicated and adverse clinicopathological findings, including older age, male gender, advanced locoregional disease, and distant metastases. Approximately 20% of patients with ATC have a history of differentiated thyroid cancer, and up to 30% of ATC cases may have associated synchronous differentiated cancer. The majority of these synchronous thyroid tumors are papillary carcinomas, although follicular types have also been reported. The transformation from differentiated to anaplastic carcinoma has been documented, with Tp53 gene inactivation playing a significant role in this progression. Thyroid-specific rearrangements such as RET/PTC and PAX8/PPARγ are rarely found in poorly differentiated or undifferentiated thyroid cancer, indicating that these genetic alterations do not predispose cells to dedifferentiation. The histological differential diagnosis for ATC includes: Metastatic disease to the thyroid (e.g., metastatic clear-cell renal carcinoma). Primary thyroid lymphoma. Primary thyroid sarcoma. Poorly differentiated thyroid carcinoma. Squamous cell thyroid carcinoma. Medullary carcinoma. The recommended treatment for anaplastic thyroid carcinoma typically involves surgery, when feasible, accompanied by chemoradiation either concurrently or sequentially. However, most cases of ATC are unresectable at presentation due to the invasion of cervical structures, and surgery primarily aims to secure the patient’s airway. Anaplastic thyroid carcinoma is generally poorly responsive to any multimodal therapy.

Thelansis’s “Anaplastic Thyroid Cancer (ATC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Anaplastic Thyroid Cancer (ATC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Anaplastic Thyroid Cancer (ATC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Anaplastic Thyroid Cancer (ATC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Anaplastic Thyroid Cancer (ATC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033